IBDEI2C1 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39549,1,4,0)
 ;;=4^H35.361
 ;;^UTILITY(U,$J,358.3,39549,2)
 ;;=^5005658
 ;;^UTILITY(U,$J,358.3,39550,0)
 ;;=H04.123^^153^1926^21
 ;;^UTILITY(U,$J,358.3,39550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39550,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,39550,1,4,0)
 ;;=4^H04.123
 ;;^UTILITY(U,$J,358.3,39550,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,39551,0)
 ;;=H35.32^^153^1926^28
 ;;^UTILITY(U,$J,358.3,39551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39551,1,3,0)
 ;;=3^Exudative Age-Related Macular Degeneration
 ;;^UTILITY(U,$J,358.3,39551,1,4,0)
 ;;=4^H35.32
 ;;^UTILITY(U,$J,358.3,39551,2)
 ;;=^5005648
 ;;^UTILITY(U,$J,358.3,39552,0)
 ;;=H35.023^^153^1926^29
 ;;^UTILITY(U,$J,358.3,39552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39552,1,3,0)
 ;;=3^Exudative Retinopathy,Bilateral
 ;;^UTILITY(U,$J,358.3,39552,1,4,0)
 ;;=4^H35.023
 ;;^UTILITY(U,$J,358.3,39552,2)
 ;;=^5005588
 ;;^UTILITY(U,$J,358.3,39553,0)
 ;;=H35.022^^153^1926^30
 ;;^UTILITY(U,$J,358.3,39553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39553,1,3,0)
 ;;=3^Exudative Retinopathy,Left Eye
 ;;^UTILITY(U,$J,358.3,39553,1,4,0)
 ;;=4^H35.022
 ;;^UTILITY(U,$J,358.3,39553,2)
 ;;=^5005587
 ;;^UTILITY(U,$J,358.3,39554,0)
 ;;=H35.021^^153^1926^31
 ;;^UTILITY(U,$J,358.3,39554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39554,1,3,0)
 ;;=3^Exudative Retinopathy,Right Eye
 ;;^UTILITY(U,$J,358.3,39554,1,4,0)
 ;;=4^H35.021
 ;;^UTILITY(U,$J,358.3,39554,2)
 ;;=^5005586
 ;;^UTILITY(U,$J,358.3,39555,0)
 ;;=H40.013^^153^1926^32
 ;;^UTILITY(U,$J,358.3,39555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39555,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,39555,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,39555,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,39556,0)
 ;;=H40.012^^153^1926^33
 ;;^UTILITY(U,$J,358.3,39556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39556,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,39556,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,39556,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,39557,0)
 ;;=H40.011^^153^1926^34
 ;;^UTILITY(U,$J,358.3,39557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39557,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,39557,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,39557,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,39558,0)
 ;;=H52.03^^153^1926^41
 ;;^UTILITY(U,$J,358.3,39558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39558,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,39558,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,39558,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,39559,0)
 ;;=H52.02^^153^1926^42
 ;;^UTILITY(U,$J,358.3,39559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39559,1,3,0)
 ;;=3^Hypermetropia,Left Eye
 ;;^UTILITY(U,$J,358.3,39559,1,4,0)
 ;;=4^H52.02
 ;;^UTILITY(U,$J,358.3,39559,2)
 ;;=^5006261
 ;;^UTILITY(U,$J,358.3,39560,0)
 ;;=H52.01^^153^1926^43
 ;;^UTILITY(U,$J,358.3,39560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39560,1,3,0)
 ;;=3^Hypermetropia,Right Eye
 ;;^UTILITY(U,$J,358.3,39560,1,4,0)
 ;;=4^H52.01
 ;;^UTILITY(U,$J,358.3,39560,2)
 ;;=^5006260
 ;;^UTILITY(U,$J,358.3,39561,0)
 ;;=H59.41^^153^1926^44
 ;;^UTILITY(U,$J,358.3,39561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39561,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
 ;;^UTILITY(U,$J,358.3,39561,1,4,0)
 ;;=4^H59.41
 ;;^UTILITY(U,$J,358.3,39561,2)
 ;;=^5006426
 ;;^UTILITY(U,$J,358.3,39562,0)
 ;;=H59.42^^153^1926^45
